Efgartigimod as a potential alternative to intravenous immunoglobulin in Guillain-Barré syndrome: a retrospective study. [PDF]
Front ImmunolLiu C +5 more
europepmc +1 more source
Evolving Paradigms in the Management of Primary Immune Thrombocytopenia in Adults: From Corticosteroids to Targeted Therapies. [PDF]
Mediterr J Hematol Infect DisMartino M +4 more
europepmc +1 more source
Efgartigimod as a salvage therapy for anti-NMDAR encephalitis patients after first-line treatment failure: a case series. [PDF]
Front NeurolZhang Y +5 more
europepmc +1 more source
Anti-IgLON5 disease presenting with myokymia and favourable response to FcRN-antagonist combined with oral glucocorticoids: case report. [PDF]
Front ImmunolShang T +5 more
europepmc +1 more source
Preliminary observations on the efficacy of efgartigimod in anti-LGI1-associated autoimmune encephalitis. [PDF]
Ther Adv Neurol DisordZuo JW +6 more
europepmc +1 more source
Case Report: Anti-LGI1 encephalitis during FcRn inhibition with efgartigimod for myasthenia gravis: implications for the limitations of IgG recycling blockade. [PDF]
Front ImmunolKomatsu Y +5 more
europepmc +1 more source
Perioperative Use of Efgartigimod Alfa, a Neonatal Fc Receptor Antagonist, to Reduce Antiphospholipid Antibody Titers and Thrombotic Risk in a Kidney Transplant Recipient. [PDF]
Kidney MedAchkar K +7 more
europepmc +1 more source
Efficacy and safety of efgartigimod in very-late-onset myasthenia gravis. [PDF]
Front ImmunolZhao Y +6 more
europepmc +1 more source
Treatment Characteristics and Healthcare Resource Utilization Among Patients with Myasthenia Gravis Initiating Rozanolixizumab: A US Claims Database Analysis. [PDF]
Neurol TherKumar M +7 more
europepmc +1 more source